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The NAD World 2.0: the importance of the inter-tissue
communication mediated by NAMPT/NAD+/SIRT1 in
mammalian aging and longevity control
Shin-ichiro Imai1
The original concept of the NAD World was proposed in 2009, providing a comprehensive framework to investigate critical issues of
biological robustness and trade-offs in mammalian aging and longevity control. Signiﬁcant progress has been made over the past
7 years, advancing our understanding of the mechanisms by which biological robustness is maintained, and providing extensive
support to the concept of the NAD World. Three key organs and tissues have been identiﬁed as basic elements in this control
system for mammalian aging and longevity: the hypothalamus as the control center of aging, skeletal muscle as an effector, and
adipose tissue as a modulator. While the hypothalamus sends a signal to skeletal muscle through the sympathetic nervous system,
adipose tissue remotely regulates hypothalamic function by coordinating NAD+ biosynthesis at a systemic level. Skeletal muscle
might also communicate with other organs and tissues by secreting various myokines. The mammalian NAD+-dependent protein
deacetylase SIRT1 and the key NAD+ biosynthetic enzyme NAMPT mediate these inter-tissue communications. In this review, the
function of each organ or tissue and their inter-tissue communications will be discussed in terms of understanding mammalian
aging and longevity control. With such an emphasis on the system architecture, the concept is now reformulated as the NAD World
2.0, providing several important predictions. The concept of the NAD World 2.0 will provide a new foundation to understand a
control system for mammalian aging and longevity and accelerate the development of an effective anti-aging intervention for
humans.
npj Systems Biology and Applications (2016) 2, 16018; doi:10.1038/npjsba.2016.18; published online 18 August 2016
INTRODUCTION
If you are asked to deﬁne ‘aging’ in one simple phrase, what
would it be? One such deﬁnition of aging could be ‘breakdown
of biological robustness’. In his insightful review article, Kitano
deﬁnes ‘robustness’ as ‘a property that allows a system to maintain
its functions against internal and external perturbations’.1 Each
individual of living species is a robust biological system, and each
biological system has been evolved to maintain its functionality
against various types of perturbations for its survival and
reproduction. A good example is the regulation of blood glucose
levels. In human adults, fasting blood glucose levels are normally
maintained within a relatively narrow range, 4–6 mmol/l. After
meals, blood glucose levels shoot up but go back to normal levels
within 2–3 h as far as insulin secretion and action are normal.
While the functionality of insulin secretion and action is
genetically deﬁned, our current life style with nutrient-dense
diets and the lack of enough exercise constantly imposes serious
perturbations to this critical functionality that our system is
designed to keep robust. Such complex interaction between
environmental and genetic factors affects a delicate balance
between insulin sensitivity and secretion, causing insulin
resistance and reduced β-cell function over time.2–4 When our
biological system can no longer maintain appropriate robustness
to keep fasting glucose levels o7 mmol/l, our system would be
derailed into a pathological condition, called type 2 diabetes.
Interestingly, people who manifest insulin resistance do not
necessarily develop type 2 diabetes,5–7 and insulin resistance and
impaired β cell function can be reversed dose-dependently by
progressive weight loss.8 Therefore, the development of insulin
resistance and the reduction in β cell function, both of which are a
part of normal aging, cannot be explained simply by aging
theories that assume probabilistic functional deterioration as a
cause of aging, such as the ‘wear and tear’ theory originally
proposed by Weismann,9 but need to be reevaluated in the light
of the mechanism of biological robustness.
Indeed, aging is the process of systemic, progressive functional
decline, and it is conceivable that such functional decline is the
result of biological robustness breakdown.10–12 To address this
idea, it is very important to understand what comprises biological
robustness in our system. System components, structure,
and dynamics need to be identiﬁed. In this regard, signiﬁcant
progress has been made in the ﬁeld of aging and longevity
research in the past 20 years, and several evolutionarily conserved
signaling pathways and regulators for aging and longevity control
have been identiﬁed: Insulin/insulin-like growth factor 1 (IGF-1)
signaling,13 mechanistic target of rapamycin (mTOR) signaling,14,15
and nicotinamide adenine dinucleotide (NAD+)-dependent
sirtuins.16,17 These key components have been shown to mediate
fundamental cellular processes that contribute to the cellular and
molecular hallmarks of aging, such as mitochondrial dysfunction,
epigenetic alterations, genomic instability, loss of proteostasis,
and others,18 and determine lifespan in diverse model organisms.
Now that we have better understanding of these regulatory
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components, it is time to elucidate the system structure and
dynamics for aging and longevity control. To achieve this goal,
we need to understand (1) in which organ or tissue each key
component plays a major role in affecting the process of aging
and determining lifespan, (2) what intrinsic and extrinsic
perturbations alter the functionality of each key component in
those speciﬁc organs and tissues, (3) where and how these
functional changes in each key component begin to affect the
biological robustness of the system, and (4) what determines
the threshold and the rate of the biological robustness
breakdown.19–21
Another critical issue to understand the process of aging and
the determination of lifespan is the role of biological trade-offs in
the context of biological robustness. Systems that have evolved to
comprise a greater scale of complexity are optimized for
perturbations they have encountered during the course of
evolution, but are also inevitably susceptible to unexpected
perturbations.1,22 In addition, robustness trade-offs extend not
only between robustness and fragility, but also between
robustness, resources, and performance.1,23 Identifying robustness
trade-offs for each biological process in different species is
critically important as the time course of aging-related break-
downs of physiological functions diverge substantially among
species, implying that each species may have their own
robustness trade-offs for each biological process. This may be a
foundation of theoretical framework where reduction of
robustness is related to reduction of other factors such as energy
supply capability that is related to resource demands. This also
suggests that biological trade-offs in resource allocation between
reproduction and late-life events, which is predicted by the
disposable soma theory proposed by Kirkwood,24 may not always
be observed, dependent on the internal conﬁguration of each
system. Indeed, at least in Caenorhabditis elegans, while somatic
tissues use their energy and resources to maintain the germ line
and thereby reproductive integrity,24 stress responses to DNA
damage in the germ line confer systemic protection of somatic
tissues against other stresses through the induction of the innate
immune response and the activation of the ubiquitin–proteasome
system.25,26 Thus, identifying trade-offs between robustness and
fragility in each biological system is critical to determine how and
where the aging process is triggered as cascading system failures
against the biological robustness in each organism.
The original concept of the NAD World was proposed in 2009 as
an attempt to address all these critical issues of biological
robustness and trade-offs in mammalian aging and longevity
control.19,20 Since then, many critical ﬁndings have been made,
adding new knowledge to further support the concept of the
NAD World. In this review, I will summarize this progress and
reformulate the concept as the NAD World 2.0, with an emphasis
on the importance of the inter-tissue communication in the
systemic regulation of mammalian aging and longevity.
THE BASIC CONCEPT OF THE NAD WORLD
The NAD World was originally proposed as a systemic regulatory
network that intimately connects NAD+ metabolism, biological
rhythm, and aging and longevity control in mammals.19–21,27,28
In the original concept, two key components comprise the NAD
World: The mammalian NAD+-dependent protein deacetylase
SIRT1, and systemic NAD+ biosynthesis mediated by nicotinamide
phosphoribosyltransferase (NAMPT), a key NAD+ biosynthetic
enzyme in mammals (Figure 1). It has been ﬁrmly established
that SIRT1 is a critical metabolic regulator in many different organs
and tissues.16,17,29,30 For instance, SIRT1 promotes glucose-
stimulated insulin secretion in pancreatic β cells, stimulates fatty
acid mobilization and adipokine production in adipose tissue,
regulates glucose and lipid metabolism in the liver, and enhances
fatty acid β-oxidation in skeletal muscle (Figure 1). Because NAD+
is absolutely required for all these important functions of SIRT1,
NAMPT-mediated NAD+ biosynthesis plays an important role in
regulating SIRT1 activity.31,32 In mammals, NAMPT has two
different forms, intracellular and extracellular NAMPT (iNAMPT
and eNAMPT, respectively; Figure 1).33,34 Surprisingly, eNAMPT has
higher enzymatic activity compared with iNAMPT,35 and its novel
function of supporting hypothalamic NAD+ has recently been
found,36 as discussed later. SIRT1 and NAMPT together regulate
the system dynamics of the NAD World. A good example of their
cooperation is the regulation of a novel circadian feedback loop
through the key circadian transcriptional regulators CLOCK/
BMAL1, producing the circadian oscillation of NAD+ in peripheral
organs and tissues and potentially in the suprachiasmatic
nucleus.37–39 This circadian oscillation of NAD+ also impacts the
activities of other sirtuins, namely mitochondrial SIRT3 and nuclear
SIRT6, allowing the circadian regulation of oxidative metabolism in
mitochondria and lipid/carbohydrate metabolism in the liver,
respectively.40,41 In this regard, the importance of SIRT6 should
also be emphasized because whole-body SIRT6-overexpressing
mice have been reported to show lifespan extension, although it
was observed only in males.42
Figure 1. The original concept of the NAD World.20 The NAD World
is a systemic regulatory network that fundamentally connects NAD+
metabolism, biological rhythm, and aging and longevity control in
mammals. Two critical components comprise the NAD World:
the mammalian NAD+-dependent protein deacetylase SIRT1,
and systemic NAD+ biosynthesis mediated by nicotinamide
phosphoribosyltransferase (NAMPT). While SIRT1 functions as a
key mediator that orchestrates metabolic responses to changes in
nutritional availability in multiple tissues, NAMPT-mediated
NAD+ biosynthesis functions as a pace maker that produces
circadian-oscillatory NAD+ production and ﬁne-tunes SIRT1 activity
at a systemic level. NAMPT has intra- and extracellular forms
in mammals, iNAMPT and eNAMPT, respectively. iNAMPT is
ubiquitously expressed, but its levels are varied (The font size
reﬂects a relative level of iNAMPT). eNAMPT, which is actively
secreted from adipose tissue and has a higher enzymatic activity
than iNAMPT, likely synthesizes nicotinamide mononucleotide
(NMN) from nicotinamide (Nic) extracellularly. The availability of
NMN is particularly important for tissues and organs that possess
very low levels of iNAMPT, such as pancreatic β cells and central
neurons. The concept of the NAD World provides several important
predictions for the biological robustness and trade-offs in
mammalian aging and longevity control. See text for details.
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Several critical predictions were made in the original concept of
the NAD World. First, the decline in systemic NAD+ biosynthesis
could be an important trigger for a variety of pathophysiological
changes that signiﬁcantly contribute to aging through decreased
activities of SIRT1 and other sirtuins. This prediction has been
demonstrated to be correct over the past 5 years. Indeed, NAMPT-
mediated NAD+ biosynthesis declines with age in multiple organs
and tissues, such as pancreas, adipose tissue, skeletal muscle, liver,
and brain,43–48 reducing the activities of SIRT1 and other sirtuins in
those organs and tissues. In addition, chronic activation of poly-
ADP-ribose polymerases (PARPs), which might potentially be
caused by a gradual accumulation of nuclear DNA damage, also
accelerates NAD+ depletion and reduces sirtuin activity.45 Second,
the concept indicated potential points of fragility in the biological
system of mammals, namely, organs and tissues that have very
low levels of iNAMPT. When systemic NAD+ biosynthesis begins to
decline, these organs and tissues would respond ﬁrst to the
change and start having functional defects due to inadequate
NAD+ biosynthesis and thereby reduced sirtuin activity. Two
strong candidates for such fragility points are pancreatic islets and
the brain (central neurons), both of which have been found to
possess very low levels of iNAMPT.35 This predicted susceptibility
of pancreatic islets and central neurons to NAD+ has
been successfully demonstrated by the fact that changing
NAD+ biosynthesis pharmacologically or genetically affects their
functionality signiﬁcantly.35,46,49,50 Last, the concept proposed that
aging is the process in which biological robustness gradually alters
and eventually breaks down according to a functional hierarchy
determined by the susceptibility to systemic NAD+ biosynthesis.
In other words, the cascade of robustness breakdown triggered by
a decrease in systemic NAD+ biosynthesis and the resultant
functional defects in susceptible organs and tissues is the central
process of aging. This particular hypothesis has been addressed by
enhancing the functionality of these fragility organs and tissues
through genetic manipulation of SIRT1,51–53 which has led us to
surprising but critical ﬁndings, as discussed in the next section.
IDENTIFYING THE HYPOTHALAMUS AS A HIGH-ORDER
CONTROL CENTER OF AGING
Given that pancreatic islets and central neurons are two strong
candidates of fragility points in the mammalian biological system,
the prediction was that overexpression of SIRT1 in these fragility
points would enhance their functionality and signiﬁcantly alter the
dynamics of the aging process, potentially extending lifespan. To
test this prediction, pancreatic β-cell-speciﬁc SIRT1-overexpressing
(BESTO) mice were generated ﬁrst.51 Interestingly, BESTO mice
showed enhancement of glucose-stimulated insulin secretion in
pancreatic islets, demonstrating the importance of SIRT1 in
pancreatic β-cell function. Other groups also conﬁrmed the
Figure 2. The hypothalamus as the high-order control center of aging. (a) SIRT1/NKX2-1/OX2R-mediated signaling in the dorsomedial and
lateral hypothalamic nuclei (DMH and LH, respectively) regulates the aging process and longevity in mammals.53 SIRT1 and its binding partner
NKX2-1 (NK2 homeobox 1) upregulate the transcription of the orexin type 2 receptor (Ox2r) gene, leading to neural activation during the dark
time. This neural activation stimulates two separate functions: one is the stimulation of skeletal muscle through the sympathetic nervous
system, which maintains mitochondrial morphology and function during the aging process, and the other is the stimulation of delta activity
in electroencephalogram, which contributes to the maintenance of the quality of sleep. These functions contribute to the promotion
of longevity. (b) NF-κB signaling in the mediobasal hypothalamus (MBH) systemically regulates aging and longevity in mammals.58 In the MBH,
NF-κB activation in microglia enhances the production of the inﬂammatory cytokine tumor necrosis factor-α (TNF-α). TNF-α then activates
NF-κB signaling in MBH neurons that produce gonadotropin-releasing hormone (GnRH). GnRH is able to prevent various age-associated
changes shown in this ﬁgure. Thus, inhibiting NF-κB signaling in the MBH prolongs lifespan, whereas activating NF-κB in the MBH shortens
lifespan in mice.
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ﬁnding.54,55 However, unexpectedly, this phenotype of BESTO
mice was lost completely when they became old.52 Importantly,
administration of nicotinamide mononucleotide (NMN), a key
NAD+ intermediate and a product of the NAMPT reaction, restored
the phenotype in aged BESTO mice and even enhanced insulin
secretion in old wild-type control mice.52 It has also been reported
that eNAMPT and NMN potentiate glucose-stimulated insulin
secretion in human islets.49 These ﬁndings strongly suggest that
pancreatic islets are indeed a fragility point that is very susceptible
to the decline in NAD+ biosynthesis. Nonetheless, upregulating
SIRT1 in pancreatic islets fails to affect the process of aging likely
due to their high susceptibility to NAD+ decline.
To examine the other candidate, central neurons, brain-speciﬁc
SIRT1-overexpressing (BRASTO) mice were generated using the
mouse prion promoter.56 Strikingly, BRASTO mice exhibited
signiﬁcant delay in aging and lifespan extension in both males
and females.53 Several physiological traits, including physical
activity, body temperature, oxygen consumption, and quality of
sleep, were signiﬁcantly maintained when BRASTO mice became
old. In particular, their skeletal muscle maintained youthful
morphology and function of the mitochondria during the aging
process,53 implicating that sarcopenia could be prevented by
stimulating SIRT1 in the brain. This phenotype is caused by
enhanced neural activity in two hypothalamic regions called the
dorsomedial and lateral hypothalamic nuclei (DMH and LH,
respectively), which stimulates skeletal muscle through the
sympathetic nervous system. SIRT1 and its binding partner
NKX2-1, an NK2 family homeodomain transcription factor,
together upregulate the expression of the orexin type 2 receptor
(Ox2r) gene, leading to neural activation in these hypothalamic
nuclei.53 Results from DMH/LH-speciﬁc Sirt1, Nkx2-1, and Ox2r
knockdown provided further support to the importance of
SIRT1/NKX2-1/OX2R-mediated signaling pathway to counteract
age-associated physiological decline (Figure 2a). In addition,
overexpressing SIRT1 only in the DMH of aged wild-type mice
restored youthful levels of physical activity and body
temperature.53 All these ﬁndings strongly suggest that neurons
in the brain, particularly those in the hypothalamus, play a crucial
role in regulating the process of aging and determining lifespan.57
Another group also reached the same conclusion regarding
the importance of the hypothalamus in mammalian aging and
longevity control. Cai’s group58 demonstrated that inhibiting
nuclear factor-κB (NF-κB) in neurons of the mediobasal
hypothalamus (MBH) extends lifespan in mice, whereas activating
NF-κB in MBH neurons shortens their lifespan. In the MBH,
microglial NF-κB activation at an earlier stage of aging results in
the production of tumor necrosis factor-α (TNF-α), which further
stimulates hypothalamic neurons and activates their NF-κB. NF-kB
activation suppresses transcription of the gonadotropin-releasing
hormone (Gnrh) gene, resulting in the decline in neurogenesis
in the hypothalamus and hippocampus, muscle strength
(endurance), muscle (ﬁber) size, skin thickness, bone mass, and
tail tendon collagen integrity (Figure 2b).58 Given that TNF-α
decreases NAMPT and NAD+ levels47 and also that SIRT1/6 and
SIRT2 could suppress NF-κB signaling in neurons and microglia,
respectively,59–61 NAD+ biosynthesis could be suppressed by
microglia-mediated inﬂammation in the hypothalamus, leading
to reduced sirtuin activity and thereby causing systemic
age-associated functional decline.
These ﬁndings strongly suggest that the hypothalamus
functions as a high-order control center of aging in mammals,
controlling the process of aging and limiting lifespan.57,58 These
recent studies also shed new light on the hypothalamic/
neuroendocrine theory of aging proposed by Dilman62 in 1971
and the concept of ‘the aging clock’ proposed by Everitt in 1973.63
Remarkably, almost a half century ago, Dilman62 already pointed
out that aging is ‘a process of disordered homeostatic stability of
internal environment’ so that ‘permanent deviations from the law
of constancy of the internal environment’ could ultimately
produce ‘the speciﬁc lesions of ageing’. It has now been suggested
that certain subsets of neurons in speciﬁc hypothalamic regions,
such as SIRT1/NKX2-1-double-positive neurons in the DMH and
GnRH-producing neurons in the MBH, might be a key fragility
point in our system, and their functional decline could trigger the
breakdown of the biological robustness at a systemic level. Given
that SIRT1 and NKX2-1 regulate orexin signaling, it is intriguing
that overexpression of the uncoupling protein 2 (UCP2) in
orexin/hypocretin neurons exhibits increased energy efﬁciency
and median lifespan extension, another support for the
importance of hypothalamic neurons in mammalian aging and
longevity control.64 Further investigation is currently ongoing to
elucidate the characteristics and the functions of these key
hypothalamic neurons in mammalian aging and longevity control.
SKELETAL MUSCLE AS AN EFFECTOR IN AGING AND
LONGEVITY CONTROL
Skeletal muscle receives a signal from the hypothalamus, a control
center of aging, through the sympathetic nervous system.65 This
stimulation increases the expression of the β2 adrenergic receptor
gene and the tissue levels of cAMP and over time maintains
mitochondrial structural integrity and function in skeletal
muscle.53,65 Most recently, the neuromuscular junction has been
identiﬁed as a target of the sympathetic nervous system, and
sympathetic input is crucial for the maintenance and function of
the neuromuscular junction.65 Obviously, the mechanics and the
regulation of skeletal muscle position it to be an actuator in the
system. However, skeletal muscle has recently been recognized as
an endocrine organ that affects the functions of other organs and
tissues through secretion of humoral factors, categorically
called myokines.66 Interestingly, we have recently found that
skeletal muscle produces a certain myokine in response to the
sympathetic nervous tone stimulated by the hypothalamus
(our unpublished ﬁnding). In ﬂies, it has been shown that skeletal
muscle modulates age-associated phenotypes at a systemic level
and eventually affects lifespan through the secretion of growth
factors and cytokines.67 For instance, Demontis and Perrimon68
demonstrated that in Drosophila, muscle-speciﬁc overexpression
of foxo and its target gene 4E-BP reduces protein aggregates via
the autophagy/lysosome system not only in muscle but also in the
retina, brain, and adipose tissue, systemically mitigating
age-associated functional decline and extending lifespan through
decreasing food intake and insulin release. The same group also
demonstrated that in Drosophila, muscle-speciﬁc overexpression
of the transcription factor Mnt, a basic helix-loop-helix factor
homologous to human MNT/MAD, decreases age-related muscle
dysfunction and ribosomal rRNA levels and nucleolar size in
adipocytes and extends lifespan through the upregulation of
Myoglianin, a myokine homologous to human myostatin and
GDF-11.69 In mammals, skeletal muscle-speciﬁc enhancement of
4E-BP activity protects against age- and diet-induced insulin
resistance and metabolic decline directly through increased
peroxisome proliferator-activated receptor γ-coactivator 1α
(PGC-1α) and enhanced respiration.70 These phenotypes,
particularly adipose phenotypes, appear to be mediated by the
myokine FGF21,70 whose overexpression has been reported to
extend lifespan in mice.71 Based on these ﬁndings, we hypothe-
size that in addition to its function as an actuator in the system,
skeletal muscle functions as an effector that regulates the
functions of other organs and tissues through the production
and secretion of speciﬁc myokines in response to a signal from
the control center of aging, namely the hypothalamus, and
contributes to the maintenance of biological robustness. In this
model, intrinsic and extrinsic perturbations to the high-order
fragility point, such as microglia-induced inﬂammation72
and constant exposure to blue light,73 could affect the
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actuator/effector function of skeletal muscle through decreased
sympathetic nervous tone, potentially triggering the breakdown
of biological robustness. To address this model, it will be of great
importance (1) to elucidate the regulation of skeletal muscle
function by the hypothalamus and the sympathetic nervous
system and (2) to identify key myokines whose production and/or
secretion are regulated by the hypothalamus and examine their
roles in the communication with other organs and tissues.
ADIPOSE TISSUE FUNCTIONS AS A MODULATOR FOR THE
CONTROL CENTER OF AGING
Adipose tissue functions not only for fat storage but also as an
endocrine organ that secretes a variety of factors, called
adipokines, including leptin, adiponectin, and resistin.74
Interestingly, both fully differentiated white and brown adipocytes
actively secrete eNAMPT, which possesses a signiﬁcantly higher
enzymatic activity than iNAMPT.35 We have recently demonstrated
that SIRT1-dependent deacetylation of iNAMPT at lysine 53 (K53)
predisposes the protein to secretion in adipocytes (Figure 3).36
Whole-body and adipose tissue-speciﬁc Sirt1 knockout mice
completely fail to secrete eNAMPT in response to fasting,
conﬁrming the physiological relevance of this SIRT1-mediated
eNAMPT secretion from adipose tissue.36 These ﬁndings reveal
that SIRT1 and NAMPT comprise a novel NAD+-regulatory
feedback loop through the regulation of eNAMPT secretion.
Surprisingly, adipose tissue-speciﬁc Nampt knockout and knockin
(ANKO and ANKI) mice exhibit reciprocal changes in circulating
eNAMPT levels, hypothalamic NAD+ levels, SIRT1 target gene
expression, and physical activity.36 The defect in physical activity
observed in ANKO mice can be ameliorated by administration of
NMN, providing support to our conclusion that hypothalamic
NAD+ biosynthesis and function are regulated by eNAMPT and its
product NMN. Furthermore, systemic injection of a NAMPT-
neutralizing antibody reduces hypothalamic NAD+ levels in vivo,
whereas treating hypothalamic explants with puriﬁed eNAMPT
enhances NAD+, SIRT1 activity, and neural activity ex vivo.36 These
ﬁndings strongly indicate that NAD+/SIRT1-mediated eNAMPT
secretion from adipose tissue plays a crucial role in remotely
regulating hypothalamic NAD+ biosynthesis and function
(Figure 3). In other words, adipose tissue functions as a modulator
for the hypothalamus, the control center of aging, through the
secretion of eNAMPT. This model leads us to an interesting
prediction that having optimal adiposity that maximizes circulat-
ing eNAMPT activity would maximize the biological robustness of
our system through the regulation of systemic NAD+ biosynthesis.
Interestingly, it has been reported that the lifespan response of 41
recombinant inbred strains of mice to diet restriction (DR), the
most reproducible experimental regimen that delays aging and
extends lifespan in a wide variety of organisms, ranges from
extension to shortening of lifespan.75 Importantly, in these strains,
the effect of lifespan extension by DR correlates inversely with fat
reduction measured at mid-life and later ages.76 In other words,
the mouse strains maintaining more fat in their later lives tend to
show longer lifespan, implicating that factors associated with
maintaining fat are important for survival and lifespan extension
under DR. Furthermore, even in the human population, it has been
well-known that very low adiposity is not associated with longer
lifespan. The optimal body mass index (BMI) that minimizes the
risk of death from any cause is 24–25 for men and 22–23 for
women, always on the slightly overweight side.77–80 People who
have BMI o20 tend to suffer from cardiovascular, neuronal, and
pulmonary diseases and have higher death rates when they
become old.77,79 Although the precise mechanisms underlying
Figure 3. The feedback mechanism between the hypothalamus and adipose tissue that maintains hypothalamic NAD+ levels through the
secretion of eNAMPT.36 In adipose tissue, iNAMPT is acetylated, and SIRT1 speciﬁcally deacetylates lysine 53 and predisposes iNAMPT to
secretion in a NAD+-dependent manner. eNAMPT secreted from adipose tissue remotely promotes NAD+ biosynthesis in the hypothalamus
likely through the extracellular synthesis of NMN and enhances SIRT1 activity and neural activity. In the DMH, SIRT1 and its binding partner
NKX2-1 regulate the transcription of Prdm13 (PR domain-containing protein 13), which controls the quality of sleep and adiposity. This
NAD+/SIRT1-mediated eNAMPT-secreting function of adipose tissue positions this tissue to be a modulator/sensor in the system. Adipose
tissue might also have another NAD+-sensing mechanism that could affect the functions of other organs and tissues. DMH, dorsomedial
hypothalamic nuclei.
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these phenomena remain unknown, it will be of great interest to
address the hypothesis that slightly higher adiposity could
optimize the functionality of the control center of aging and
minimize the risk of death.
This inter-tissue communication between the hypothalamus
and adipose tissue likely comprises a critical feedback loop for
aging and longevity control (Figure 3). Many studies have already
demonstrated that different hypothalamic nuclei regulate adipose
tissue through the autonomic nervous system.81 We identiﬁed
Prdm13 (PR domain-containing protein 13) as a gene highly and
selectively expressed in the DMH.82 The expression of Prdm13 in
the hypothalamus increases under DR, whereas it decreases
during aging. In addition, its expression also shows robust diurnal
oscillation and is signiﬁcantly upregulated in the DMH of
long-lived BRASTO mice. Interestingly, DMH-speciﬁc Prdm13-
knockdown mice exhibit a signiﬁcant defect in sleep quality
during non-REM sleep and a progressive increase in adiposity, two
common age-associated complications in rodents and humans
(Figure 3).82 Nonetheless, these mice show no change in their food
intake, suggesting that PRDM13 in the DMH directly regulates
adiposity. Given that Prdm13 is under the regulation of the
SIRT1/NKX2-1-mediated signaling pathway in the DMH,82 the
hypothalamus as the control center of aging and adipose tissue as
a modulator comprise a complex NAD+-dependent feedback loop
through these key players. For instance, when NAMPT and NAD+
levels decrease over age in adipose tissue,47 this would decrease
SIRT1 activity and secretion of enzymatically active eNAMPT from
adipose tissue to blood circulation. Decreasing circulating
eNAMPT activity would affect NAD+ biosynthesis and SIRT1
activity in the hypothalamus, leading to decreased Prdm13
expression in the DMH over age.82 Decreased PRDM13 activity
in the DMH would stimulate adipose tissue probably through the
sympathetic nervous system, increasing adiposity to compensate
the decrease in eNAMPT secretion in aged individuals. In this
model, one interesting question is whether adipose tissue can also
function as a sensor that detects NAD+ changes sensitively and
sends signals to other organs and tissues (Figure 3). Further
investigation will be necessary to address this interesting
possibility. Another interesting question is whether enforcing this
feedback loop between the hypothalamus and adipose tissue
could affect the system dynamics of the aging process and
contribute to the determination of lifespan in mammals. This
particular question is currently being addressed by analyzing
ANKI mice.36
NAD WORLD 2.0: A SYSTEMS-BIOLOGICAL APPROACH TO
UNDERSTAND, AND CONTROL AGING AND LONGEVITY IN
MAMMALS
As summarized above, these new ﬁndings over the past 7 years
have signiﬁcantly advanced our understanding of the system
architecture for mammalian aging and longevity control,
providing critical information that deepens the original concept
of the NAD World. In particular, identifying the inter-tissue
communication between the hypothalamus, skeletal muscle, and
adipose tissue provides new insights into how biological
robustness is regulated throughout our biological system in terms
of understanding mammalian aging and longevity control.
Although further extensive studies will be required to elucidate
the entire system architecture of the NAD World, it has at
least basic elements of a control system from an engineering
point-of-view: The hypothalamus as the controller, skeletal muscle
as an actuator, and adipose tissue as a possible sensor. As
discussed in previous sections, however, each organ or tissue
usually has more than one function designated by a speciﬁc
engineering term. Thus, both biological and engineering terms are
used in parallel to further describe the functionality of these
organs and tissues in the NAD World (Figure 4).
How is the NAD World controlled? As a control system, the
following three mechanisms play a critical role in controlling the
NAD World:
(1) The NAD+-driven regulation of SIRT1 activity in a speciﬁc
subset of hypothalamic neurons, such as SIRT1/NKX2-1-
double-positive neurons in the DMH (Figure 4). Maintaining
appropriate activity levels of SIRT1, likely as well as other
sirtuins, in these speciﬁc hypothalamic neurons is critical to
control the function of skeletal muscle as an actuator,
determining physical activity levels of individuals.36,53 This
particular signal also stimulates the effector function of
skeletal muscle, producing certain speciﬁc myokines and
possibly affecting the hypothalamus or other organs and
tissues (Figure 4). Prdm13, a downstream target of the
SIRT1/NKX2-1 signaling, also negatively regulates adiposity.82
In this regard, the level of hypothalamic NAD+ is the critical
target of control, and it is regulated by the feedback loop
between the hypothalamus and adipose tissue. Importantly,
the set point of hypothalamic NAD+ could be affected by
internal and external perturbations and thereby shifted over
time, which could derail the entire system from the range of
biological robustness.
(2) The feedback loop between the hypothalamus and adipose
tissue through the secretion of enzymatically active eNAMPT
(Figures 3 and 4). As discussed in the previous section, the
secretion of eNAMPT is regulated by adipose NAD+ and
SIRT1,36 which positions adipose tissue to be a sensor of NAD+
in the system. In addition, adipose tissue modulates NAD+
levels in a circadian-oscillatory manner, propagating its
internal rhythm to other organs and tissues, including the
hypothalamus. It should be noted that adipose NAD+ levels
are an independent valuable that could be affected by
different perturbations with different time constants. Because
eNAMPT plays an important role in coordinating systemic
Figure 4. The concept of the NAD World 2.0. The original concept of
the NAD World is now reformulated as the NAD World 2.0, with an
emphasis on the importance of the inter-tissue communication
between three key organs and tissues, namely, the hypothalamus
as the control center of aging/controller, skeletal muscle as an
effector/actuator, and adipose tissue as a modulator/possible sensor
(both biological and engineering terms are described in parallel).
Cooperative functions of SIRT1 and NAMPT, both iNAMPT and
eNAMPT, play a crucial role in regulating the system dynamics of this
inter-tissue communications. The NAD World 2.0 as a control system
provides new insights into the regulation of biological robustness
and fragility in mammalian aging and longevity control. See text for
details.
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NAD+ biosynthesis, its reaction product, NMN, must have an
important function to maintain the biological robustness
throughout the system. Indeed, it has already been
demonstrated that NMN shows remarkable effects of
ameliorating disease conditions, including type 2 diabetes,
ischemia/reperfusion injury, and Alzheimer’s disease.47,83–85 In
this regard, how NMN uptake is regulated is another important
target of control, and intensive investigation is currently
underway to address this critical issue.
(3) Another possible feedback loop between the hypothalamus
and skeletal muscle through the secretion of speciﬁc myokines
(Figure 4). Compared with the other two mechanisms, this
particular feedback mechanism is rather speculative at this
moment. Nonetheless, different from other tissues, one
important feature that skeletal muscle has is a feed-forward
control of its own NAD+ biosynthesis in response to exercise.
It has been demonstrated that skeletal muscle induces NAMPT
and NAD+ levels in response to exercise in rodents and
humans.86–88 Given that skeletal muscle functions as an
effector/actuator, this speciﬁc feature of skeletal muscle likely
plays an important role in enhancing a signal back to the
hypothalamus or to other organs and tissues, enforcing the
strength of this feedback mechanism and contributing to
the maintenance of biological robustness. Further studies will
be necessary to elucidate molecular details of the feedback
mechanisms that skeletal muscle mediates in this control
system.
This reformulated version of the NAD World concept, now
called the NAD World 2.0, deﬁnes the system architecture for
mammalian aging and longevity control, and provides several
interesting predictions to further investigate this control system.
First, any perturbations to NAD+ levels in the hypothalamus,
particularly in key hypothalamic neurons, could change the
process of aging and eventually affect lifespan. Hypothalamic
neurons are a critical fragility point, and their function could be
impaired by even a slight decrease in NAD+ availability, potentially
caused by accumulation of inﬂammation and other damages.72
When the feedback loop between the hypothalamus and adipose
tissue functions normally, such decreases in hypothalamic NAD+
levels could be compensated by increasing eNAMPT
secretion from adipose tissue. However, NAMPT-mediated NAD+
biosynthesis also independently declines over age in adipose
tissue, likely due to chronic inﬂammation developed within
adipose tissue. Thus, the system would eventually reach a point
where the robustness of this feedback loop between the
hypothalamus and adipose tissue can no longer be maintained.
Once this breakdown starts happening, the hypothalamus would
lose its function and eventually derail the entire system. If this is
the case, any manipulation that enhances the resilience of key
hypothalamic neurons against such NAD+ reduction could
counteract age-associated functional decline and possibly extend
lifespan in mammals. To address this prediction, it will be of great
importance to examine the aging process and the lifespan of ANKI
mice that have increased levels of circulating eNAMPT.36 ANKI
mice are predicted to preserve hypothalamic NAD+ and function
longer than control wild-type mice and show signiﬁcant delay in
aging and possibly lifespan extension.
Second, the feedback mechanism between the hypothalamus
and adipose tissue predicts the importance of NMN as a systemic
signaling molecule that maintains biological robustness. Given
that NAD+ levels decline with age in various organs and tissues in
rodents and humans,43–48 boosting NAD+ biosynthesis with NMN
or nicotinamide riboside, another NAD+ intermediate that is
converted to NMN, in key system-controlling organs and tissues
could maintain biological robustness and delay the aging process
in mammals.43,47,89,90 In particular, when the feedback mechanism
can no longer maintain normal NAD+ levels in the hypothalamus,
intervening the system with NMN administration would be
expected to normalize hypothalamic NAD+ levels and ameliorate
‘hallmarks of aging’, including inter-cellular or inter-tissue
communications.18 In this regard, sarcopenia would be an
interesting model to test this prediction. As observed in aged
BRASTO mice, an enhanced signal from the hypothalamus would
be expected to maintain the structure and the function of skeletal
muscle as an effector/actuator. NMN treatment would be able to
achieve this goal through the stimulation of hypothalamic
function.
Third, speciﬁc myokines secreted from skeletal muscle in
response to signals from the hypothalamus would affect the
process of aging and possibly lifespan in mammals. Potentially,
these myokines might be an important part of the feedback
mechanism between the hypothalamus and skeletal muscle. In
this regard, FGF21 is an interesting candidate. It has been reported
that FGF21 acts directly on the suprachiasmatic nucleus of the
hypothalamus and the dorsal vagal complex of the hindbrain,
mimicking the physiological response to fasting.91 Overexpression
of FGF21 has also been reported to extend lifespan in mice.71
Another interesting candidate is myostatin (GDF-8), a myokine
that negatively regulates muscle mass. Interestingly, myostatin-
deﬁcient heterozygous mice have been reported to show 10% and
16% extension for median and maximal lifespan, respectively.92
There may be other myokines that can affect other hypothalamic
nuclei, such as DMH, and comprise a feedback loop between the
hypothalamus and skeletal muscle. This prediction is currently
being tested by manipulating a myokine identiﬁed to respond to a
signal from the hypothalamus.
CONCLUDING REMARKS
The NAD World 2.0 is a reformulated version of the original
concept of the NAD World, emphasizing the importance of the
inter-tissue communications between the hypothalamus as the
control center of aging/controller, skeletal muscle as an effector/
actuator, and adipose tissue as a modulator/possible sensor in the
systemic regulation of aging and longevity in mammals. Although
further investigation is absolutely necessary to dissect precise
details of the system dynamics in this control system, the NAD
World 2.0 provides new insights and predictions into how we can
better understand mammalian aging and longevity control and
how we can manipulate such a control system to alter the process
of aging and longevity. It will be of great importance to further
elucidate the kinetics of feedback mechanisms between the
hypothalamus and adipose tissue or skeletal muscle. Of course,
other organs and tissues might also be important, adding more
layers of regulation to this control system. In addition, further
investigating the features of key fragility points, particularly
hypothalamic neurons that have very low levels of iNAMPT, will
provide critical insights into how biological robustness breakdown
contributes to the aging process. Last, by taking such a systems-
biological approach, we will be able to develop an effective
intervention, using NAD+ intermediates such as NMN and NR,
which would allow us to control the aging process and eventually
extend healthspan and lifespan in humans. In the next 5–10 years,
new exciting progress in the ﬁeld of aging and longevity research
will surely drive further evolution of the concept of the NAD
World 2.0.
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